Payment overview · 2025
General Payments
$1,905.34
71 reported records · 29 companies
Healthcare provider profile · identity verified
Caitlin Brooks Piteck, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · SAN DIEGO, CA · NPI 1528749124
Verified facts
What the public records show
CMS Open Payments records show Caitlin Brooks Piteck, NP received $1,905.34 in general payments during 2025 across 71 reported records.
Novo Nordisk Inc accounted for 11.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $217.18 | 11.4% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $175.26 | 9.2% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $160.97 | 8.4% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $150.18 | 7.9% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $145.26 | 7.6% | 8 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $137.92 | 7.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $112.23 | 5.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $80.18 | 4.2% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $79.04 | 4.2% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $59.69 | 3.1% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $52.18 | 2.7% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $51.27 | 2.7% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $45.97 | 2.4% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $43.23 | 2.3% | 2 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $43.01 | 2.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $42.28 | 2.2% | 2 | 2025 |
| QIAGEN, LLC | Unresolved — no canonical attribution shown | $39.84 | 2.1% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $29.74 | 1.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $28.94 | 1.5% | 1 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $27.12 | 1.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $26.09 | 1.4% | 1 | 2025 |
| TMS NeuroHealth Centers Inc. | Unresolved — no canonical attribution shown | $25.40 | 1.3% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $23.04 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.63 | 1.2% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $22.45 | 1.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $19.88 | 1.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $16.52 | 0.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.04 | 0.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.80 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,905.34 | 71 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $137.92 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $132.57 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $119.28 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $115.16 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $112.23 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $103.04 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $102.72 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $102.72 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $102.46 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $79.04 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $66.90 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $61.04 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $57.93 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $52.18 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $51.27 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $45.97 | 2 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $43.23 | 2 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $43.01 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $42.28 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $42.28 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $36.94 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $29.74 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $28.94 | 1 | 2025 |
Source payment records
|
|||||
| OPZELURA Normalized: opzelura |
Drug | Incyte Corporation | $27.12 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $26.09 | 1 | 2025 |
Source payment records
|
|||||
| TMS NeuroHealth Centers Inc. Normalized: tms neurohealth centers inc |
Device | TMS NeuroHealth Centers Inc. | $25.40 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $23.04 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $22.45 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.52 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.52 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.80 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $12.69 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 25 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 25 | 11 |
| Trazodone Hcl | Trazodone Hcl | 23 | suppressed |
| Losartan Potassium | Losartan Potassium | 19 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 19 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 17 | suppressed |
| Eliquis | Apixaban | 16 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Lisinopril | Lisinopril | 13 | suppressed |
| Metformin Hcl | Metformin Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,905.34 · 71 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, APRETUDE, APTIMA, AREXVY, AUSTEDO XR, BREZTRI, COMIRNATY, Cologuard Collection Kit, DUPIXENT, Extended Holter, FARXIGA, INSPIRE, ImmunoCAP, JARDIANCE, KISUNLA, Kerendia, Korlym, LEQVIO, MOUNJARO, NEXLETOL, NEXPLANON, OPZELURA, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, RELISTOR, REPATHA, Rybelsus, SHINGRIX, SPRAVATO, Saxenda, TMS NeuroHealth Centers Inc., TRELEGY ELLIPTA, TZIELD, UBRELVY, Wegovy, XIFAXAN, XYOSTED, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error